Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06967389 · ClinicalTrials.gov registry record
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
A clinical trial of Weight Loss and Obesity and Overweight, sponsored by John Bauer.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT06967389: Recruiting study of Weight Loss and Obesity and Overweight, sponsored by John Bauer.
NCT06967389 is a study of Weight Loss and Obesity and Overweight that is actively recruiting participants, run by John Bauer. The registered enrollment target is 50 participants, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06967389, a study of Weight Loss and Obesity and Overweight, is actively recruiting participants, sponsored by John Bauer.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are: * How do the rate of weight loss, body mass index (BMI), body composition, heart structure and function, and exercise ability interact with one another in the study population at enrollment? * How do risk markers of disease change over the study in the study participants who are given semaglutides to help with weight loss? * Are there differences in the above factors between males and females and are there key factors to help improve the outcomes? Participants will be given semaglutide for this study. During the course of the study, participants will: * have two cardiac MRI scans OR two cardiac echocardiograms (one before starting semaglutide and one around 12 months after taking the drug) * have body composition and fitness levels assessed twice (before semaglutide and around 12 months after taking it) and have urine specific gravity (USG) measured * have extra blood drawn when labs their doctor orders are already being drawn (once at the beginning of the study, once around 6 months after enrollment, and once at the end of the study) * have follow up visits with the study doctor * be asked to take a pregnancy test if they are female and have started menstruation
Primary Outcome
This will be assessed by reviewing changes in the electronic medical record
Conditions Studied
Interventions
- DRUG Ozempic®
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-06-12 |
| Est. Completion | 2027-07 |
What NCT06967389 shows while recruiting
NCT06967389 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (97% lower).
The record links to 5 conditions, with Weight Loss appearing as the primary indexed condition, and to 1 intervention - of which Ozempic® is the first listed.
NCT06967389 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT06967389 about?
NCT06967389 is a clinical study titled "Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity". The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are: * How do the rate of weight loss, body mass index (BMI), body composit...
What is the current status of trial NCT06967389?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-06-12. Estimated completion is 2027-07.
What conditions does trial NCT06967389 study?
This clinical trial studies the following conditions: Weight Loss, Obesity and Overweight, Weight Management, Obese Adolescents, Cardiovascular Disease Risk Factor.
What interventions are being tested in trial NCT06967389?
The interventions under investigation include: Ozempic® (DRUG).
Who is sponsoring clinical trial NCT06967389?
This trial is sponsored by John Bauer, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06967389 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06967389's enrollment target sits among peer trials
50 76th of 116 higher than 39 of 116 other Weight Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Weight Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss
RECRUITING
-
Metabolic Health, Bones and Nuts During Weight Loss in Adults
RECRUITING · NA
-
FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
RECRUITING · NA
-
Exercise Effects on Adipose Tissue Structure and Function
RECRUITING · NA
-
Fasted vs. Fed State Exercise
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI